Get the Stockscreener App
0.61
1.18%
0.0071
After Hours:
.59
-0.02
-3.28%
Bioxcel Therapeutics Inc stock is traded at $0.61, with a volume of 462.02K.
It is up +1.18% in the last 24 hours and down -0.81% over the past month.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
See More
Previous Close:
$0.6029
Open:
$0.61
24h Volume:
462.02K
Relative Volume:
0.76
Market Cap:
$25.16M
Revenue:
$1.38M
Net Income/Loss:
$-179.05M
P/E Ratio:
-0.0858
EPS:
-7.11
Net Cash Flow:
$-155.03M
1W Performance:
+5.35%
1M Performance:
-0.81%
6M Performance:
-78.37%
1Y Performance:
-75.89%
1-Day Range:
$0.605
$0.635
1-Week Range:
$0.505
$0.635
52-Week Range:
$0.505
$5.6199
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Name
Bioxcel Therapeutics Inc
Sector
Industry
Phone
203-643-8060
Address
555 LONG WHARF DRIVE, NEW HAVEN, CT
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-10-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-01-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-06-22 | Reiterated | BofA Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-30-20 | Initiated | Goldman | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Aug-17-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-04-20 | Initiated | Guggenheim | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
View All
Bioxcel Therapeutics Inc Stock (BTAI) Latest News
The Potential Rise in the Price of BioXcel Therapeutics Inc (BTAI) following insiders activity - Knox Daily
BioXcel Therapeutics Inc: Weathering Stock Market Storms with 24.56M Market Cap - The InvestChronicle
Taking on analysts’ expectations and winning: BioXcel Therapeutics Inc (BTAI) - SETE News
BioXcel Therapeutics stock hits 52-week low at $0.53 By Investing.com - Investing.com Australia
BioXcel Therapeutics stock hits 52-week low at $0.53 - Investing.com
BTAI underperforms with a -2.28 decrease in share price - US Post News
Bank of New York Mellon Corp Buys 49,863 Shares of XBiotech Inc. (NASDAQ:XBIT) - Defense World
Is it a good time to sell Xcel Energy, Inc. [XEL] shares after an insider sold 2,041 shares? - Knox Daily
Blair William & Co. IL Has $2.01 Million Stock Position in Xcel Energy Inc. (NASDAQ:XEL) - Defense World
New Haven-based BioXcel faces delisting from Nasdaq stock exchange - Hartford Business Journal
Gaining Ground: BioXcel Therapeutics Inc (BTAI) Closes Lower at 0.58, Down -12.13 - The Dwinnex
Charting the Course: BioXcel Therapeutics Inc’s BTAI Stock Prospects - The InvestChronicle
Xcel Energy Inc. (NASDAQ:XEL) Shares Acquired by Sei Investments Co. - Defense World
Gabelli Funds LLC Sells 12,283 Shares of Xcel Energy Inc. (NASDAQ:XEL) - Defense World
BlackSky target adjusted to $15 from $2.50 at H.C. Wainwright - TipRanks
Summit Trail Advisors LLC Boosts Stock Position in Xcel Energy Inc. (NASDAQ:XEL) - Defense World
BlueLinx Holdings Inc. (NYSE:BXC) Shares Purchased by Massachusetts Financial Services Co. MA - Defense World
BioXcel Therapeutics faces Nasdaq delisting risk over share price - Investing.com
BioXcel Therapeutics faces Nasdaq delisting risk over share price By Investing.com - Investing.com Canada
BioXcel Therapeutics faces Nasdaq delisting risk over share price By Investing.com - Investing.com Australia
Meiji Yasuda Asset Management Co Ltd. Has $1.13 Million Holdings in Xcel Energy Inc. (NASDAQ:XEL) - Defense World
BioXcel Therapeutics faces Nasdaq delisting risk over share price By Investing.com - Investing.com UK
New Haven pharma firm BioXcel cuts jobs, shifts focus to agitation drug - CT Insider
New Haven pharma firm BioXcel cuts jobs, shifts focus to agitation drug - Greenwich Time
New Haven pharma firm BioXcel cuts jobs, shifts focus to agitation drug - Torrington Register Citizen
New Haven pharma firm BioXcel cuts jobs, shifts focus to agitation drug - The Advocate
BioXcel announces new priorities - The Pharma Letter
HC Wainwright Weighs in on BriaCell Therapeutics Corp.’s FY2029 Earnings (TSE:BCT) - Defense World
BioXcel Therapeutics (NASDAQ:BTAI) & Xenon Pharmaceuticals (NASDAQ:XENE) Head to Head Review - Defense World
Xcel Energy receives hold rating with $70 price target from Jefferies - Investing.com
BioXcel stock gains after new strategic focus (NASDAQ:BTAI) - Seeking Alpha
BioXcel Therapeutics refocuses on BXCL501 clinical trials - Investing.com
BioXcel Therapeutics announces workforce reduction to prioritize lead asset - Investing.com
New Haven-based BioXcel lays off 28% of workforce, including chief commercial officer - Hartford Business Journal
BioXcel Therapeutics refocuses on BXCL501 clinical trials By Investing.com - Investing.com Australia
BioXcel Therapeutics refocuses on BXCL501 clinical trials By Investing.com - Investing.com Canada
BioXcel announces clinical prioritization of late-stage BXCL501 programs - TipRanks
Bioxcel Therapeutics Announces Restructuring and Leadership Changes - TipRanks
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation - GlobeNewswire
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation - StockTitan
BioXcel Therapeutics CSO sells $244 in stock - Investing.com India
Bioxcel therapeutics executive sells over $148 in stock By Investing.com - Investing.com Australia
Bioxcel therapeutics executive sells over $148 in stock By Investing.com - Investing.com Canada
Bioxcel therapeutics executive sells over $148 in stock By Investing.com - Investing.com South Africa
BioXcel Therapeutics CEO sells over $1,300 in stock - Investing.com India
BioXcel Therapeutics CSO sells $244 in stock By Investing.com - Investing.com Australia
BioXcel Therapeutics executive sells shares worth $238 - Investing.com
BioXcel Therapeutics CEO sells over $1,300 in stock - Investing.com
Bioxcel therapeutics executive sells over $148 in stock - Investing.com
BioXcel Therapeutics CEO sells over $1,300 in stock By Investing.com - Investing.com UK
What is BioXcel Therapeutics Inc (BTAI) Stock Return on Shareholders’ Capital? - SETE News
Bioxcel Therapeutics Inc Stock (BTAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):